Acquisitions Establish Biotech's Maturity
619348
During the past few months some of the world's largest life-sciences firms -- desperate for new products and technology -- have gone shopping in, of all places, Gaithersburg.
337666
SAN FRANCISCO -- Billionaire investor Carl C. Icahn was given clearance by US antitrust regulators to purchase shares in Biogen Idec Inc., the world's biggest maker of drugs for multiple sclerosis.
668287
Traditional drug companies want what biotech companies have. Will the infatuation last?
394781
CV Therapeutics out-licenses one of its technologies.
449893
As key technical obstacles restricting the niche RNA interface (RNAi) industry were overcome this week, insiders are anticipating its transformation into a major biotech moneymaker.
226441
Biotechnology companies are betting that pairing old drugs can be a better business than inventing new ones from scratch.
110046
Some business software vendors are determined to steer their own ships in a sea of acquisitions.
667096
The biotech's new cancer candidate passes phase 1 trials.
447760
Hard-earned tips from a biotech investor.
727152
New developments are brewing at the pharmaceutical.
94220
While bigger competitors stumble over each other, Bio-Reference keeps growing.
160226
The contract drug research company shares surged as the firm showed signs of new life.
644960
It began in July: Mylan Laboratories (nyse: MYL - news - people ) announced it would bid $4 billion in stock for King Pharmaceuticals (nyse: KG - news - people ). Investors were less than unanimously thrilled
75091
The world's largest generics maker continues to post strong growth by bedeviling Big Pharma.
356950
Consolidation in Europe's drugs   sector gathered steam on Thursday as Germany's Merck unveiled a   $13.3-billion deal to buy Europe's top biotech firm Serono, and   Denmark's Nycomed won the drugs unit of Altana.
627268
By Sharon Smyth  Merck, the German pharmaceutical company that failed to buy a rival, Schering, this year, agreed to buy the stake owned by the billionaire Ernesto Bertarelli in Serono to obtain control of the largest biotechnology company in Europe.
607613
Genzyme Corp. said it completed its $345 million acquisition of Bioenvision Inc. despite complaints by some Bioenvision shareholders the price the Cambridge biotech offered was too low. Genzyme initially tried to take control of the New York biotech through a tender offer, but managed to acquire only 22 percent of shares that way. Bioenvision then tried to persuade a majority ...